. HTLV-I is endemic in Southwestern Japan, Central Africa, and the Caribbean basin. Human T-cell leukemia virus type two (HTL V-Il), another virus related to HTLV-I, has been linked to two cases of an atypical variant of hairy cell leukemia4. HTLV-II has been identified in IV drug abusers in the United States7.
repeatedly reactive samples were further confirmed by a new dot blot confirmatory immunoassay using highly purified HTLV-I viral and recombinant proteins as an antigen source (Abbott Laboratories, North Chicago, IL). Samples were considered serologically positive if antibodies against both the gag (p24) and env (p21E) gene products were present, according to American Health Services recommendations for laboratory techniques6. Confirmed samples were also tested forantibodies to HTLV-1 or II using a series of synthetic peptidecoated polystyrene beads in a solid phase EIA (Abbott).
This study demonstrated a relatively high prevalence of antibody to HTLV-1 (1.8%) among adults representig the general population in Bahia (Table 1 ). This rate is higher than that reported in blood donors in the United States (0.025%) 10, and in Britain (0.01 %)9. And, it is similar to antibody rates observed in African population in Gabon (3.9%), Kenya (1.7%), Liberia (1.6%), Nigeria (2.6%), Senegal (1.2%) and Zaire (3.2% )3. This similarity, presumably, reflects the African origin of the population in Bahia.
A high prevalence of HTLV-I infection was detected among patient groups, regardless of whether their diseases were HTLV-I related or not. 
